Neda Razavi, MBA
About Neda Razavi, MBA
Neda Razavi is the CEO of a company that developed the world's first AI-driven portable and automated 3D breast ultrasound scanner, which has received FDA 510(k) clearance.
Neda Razavi CEO
Neda Razavi is the CEO of a notable company in the medical device industry. She holds a leadership position and is actively involved in guiding the strategic direction of the company. Under her supervision, the company has made significant advancements in medical technology. Her role as CEO is prominently highlighted on the company's website, where she is also featured with a professional headshot.
Neda Razavi Education and Expertise
Neda Razavi holds an MBA, which equips her with robust knowledge in business management and operational strategy. Her expertise in these areas is pivotal to her role as CEO, especially in a highly competitive and regulated industry like medical devices. The combination of her educational background and hands-on experience contributes greatly to the company's success and innovation.
Neda Razavi 3D Breast Ultrasound Scanner Development
Neda Razavi was part of the team that developed the world's first AI-driven portable and automated 3D breast ultrasound scanner. This innovative medical device represents a significant leap forward in diagnostic technology, combining artificial intelligence with practical medical applications to improve patient outcomes.
Neda Razavi Social Media Presence
Neda Razavi maintains an active presence on LinkedIn and Twitter. Through these platforms, she engages with industry professionals, shares insights related to her field, and stays updated with the latest trends and advancements in medical technology. Her social media activity helps in building professional networks and fostering industry connections.
Neda Razavi FDA 510(k) Clearance
Under the leadership of Neda Razavi, the company has received FDA 510(k) clearance for their medical device. This clearance is crucial as it validates the safety and efficacy of their product, enabling it to be marketed and used in the medical field. Achieving this regulatory milestone is a testament to the company's commitment to quality and innovation in healthcare.